Abstract
Purpose: :
To determine the change of intravitreal VEGF A, monocytic adhesion protein = MCP, and IL-6 levels in ARMD, DME and CRVO.
Methods: :
Twenty patients (80.9 years, 11 male) with wet ARMD, 3 with DME (62.6 years, 3 male), and 3 with CRVO (65.3 years, 1 male) underwent 0.5 to 1ml core pars plana vitrectomy (cppV) with subsitutition of 1.5mg bevacizumab and 800µg dexamthasone as a first line combined treatment to treat ME. The levels of VEGF, IL-6, and MCP were examined with cytometric bead assay from the aspired vitreous specimen (T1). Retreatment was conducted on clinical relevant increase in CMT and BCVA decrease (T2).
Results: :
Twenty specimen (10 pseudophakia) at T1 and twelve at T2 (27.7 weeks after T1) from ARMD patients yielded VEGF A levels of totally 10.1 pg/dl (T1=5.5; T2=17.7), Il-6 of 63.1 (62.7; 63.8), and MCP 886.9 (793.9;1041.8) . There was no statistic difference between pseudophakic or phakic patients. In DME VEGF A was 46.5, IL-6 23.6, and MCP 614.3 pg/dl. In CRVO VEGF A was 190.4, Il-6, 25.4, and MCP 612.5 pg/dl.
Keywords: growth factors/growth factor receptors • vascular endothelial growth factor • inflammation